Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 5/20 | 0.65 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.65 |
| ▸ | REN | P00797 | 6/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 6/20 | 0.56 |
| ▸ | NPY4R | P50391 | 6/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.56 |
| ▸ | NPY1R | P25929 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337899 | 0.91 | AGTR1 (0.69) | AGTR1AGTR2REN | |
| SCHEMBL118957 | 0.84 | MAPK8 (0.60) | OPRM1OPRK1NPY2RNPY4RNPY5R | |
| SCHEMBL29393119 | 0.83 | AGTR2 (0.69) | AGTR1AGTR2RENNPY2RNPY4R | |
| SCHEMBL29471347 | 0.83 | AGTR2 (0.69) | AGTR1AGTR2RENNPY2RNPY4R | |
| SCHEMBL29647870 | 0.83 | AGTR1 (0.73) | AGTR1AGTR2REN | |
| SCHEMBL29599255 | 0.82 | AGTR2 (0.90) | AGTR1AGTR2REN | |
| SCHEMBL29599270 | 0.82 | OPRD1 (0.71) | AGTR1AGTR2OPRM1OPRD1OPRK1 | |
| SCHEMBL29382642 | 0.81 | AGTR2 (0.78) | AGTR1AGTR2REN | |
| SCHEMBL28485749 | 0.81 | AGTR2 (0.94) | AGTR1AGTR2 | |
| SCHEMBL29619824 | 0.81 | AGTR2 (0.94) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727937-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | Vivoryon Therapeutics N.V. (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260001873-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2026-01-01 | — | — | US | claimed |
| US-12384772-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-12 | — | — | US | claimed |
| US-20250026738-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | VIVORYON THERAPEUTICS N.V. (DE) | 2025-01-23 | — | — | US | claimed |
| WO-2024256618-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | VIVORYON THERAPEUTICS N.V. (DE) | 2024-12-19 | — | — | WO | claimed |
| CN-117024352-A | Novel inhibitors | 维沃里翁治疗股份有限公司 | 2023-11-10 | — | — | CN | claimed |
| US-20220274977-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2022-09-01 | — | — | US | claimed |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4727937-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | Vivoryon Therapeutics N.V. (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-14 | — | — | US | disclosed |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260015665-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-11340224-B2 | Whole brain lysate antigen-specific memory B cell and antibody assays in multiple sclerosis | CELLULAR TECHNOLOGY LIMITED (US) | 2022-05-24 | — | — | US | disclosed |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | disclosed |
| EP-3966223-A1 | PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3966201-A1 | THIOSEMICARBAZATES AND USES THEREOF | The Feinstein Institutes for Medical Research (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126619-A | Compounds for the synthesis of peptidomimetics | 范因斯坦医学研究院 | 2022-03-01 | — | — | CN | disclosed |
| CN-108218849-B | Novel inhibitors | 维沃永治疗公众有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001873-A1 | NOVEL INHIBITORS | GLS, GLS2, SULT1E1 | AGTR1 366/4885AGTR2 322/4885REN 160/4885 |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | AGTR1 580/4885AGTR2 617/4885REN 1396/4885 |
| US-20260015665-A1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | CD59, MASP2, CD58 | AGTR1 2433/4885AGTR2 2990/4885REN 3957/4885 |
| US-20260070894-A1 | COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS | NPR1, NGLY1, DDAH1 | AGTR1 312/4885AGTR2 526/4885REN 170/4885 |
| US-12595233-B2 | Thiosemicarbazates and uses thereof | TST, THRB, HSPB1 | AGTR1 883/4885AGTR2 1608/4885REN 508/4885 |
| US-12384772-B2 | Inhibitors | GLS, QPCT, GLS2 | AGTR1 969/4885AGTR2 398/4885REN 306/4885 |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | QPCT, QPCTL, GLUL | AGTR1 1418/4885AGTR2 1250/4885REN 1136/4885 |
| US-20250026738-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | QPCT, GLS, QPCTL | AGTR1 600/4885AGTR2 233/4885REN 129/4885 |
| US-12600699-B2 | Thiosemicarbazates and uses thereof | MET, THRB, ABAT | AGTR1 539/4885AGTR2 1134/4885REN 511/4885 |
| US-20220274977-A1 | NOVEL INHIBITORS | GLUL, GLS, QPCT | AGTR1 812/4885AGTR2 754/4885REN 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.